Reaction
Gingival Recession reporting signals
As of the last recalculation, Gingival Recession appears in 1,891 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is CHLORHEXIDINE GLUCONATE (PRR 23.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Chlorhexidine Gluconate | 19 | 23.1 | 23.2 |
| Finasteride | 86 | 16.4 | 16.4 |
| Alendronate Sodium | 129 | 15.0 | 15.0 |
| Buprenorphine Hydrochloride, Naloxone Hydrochloride | 29 | 13.4 | 13.4 |
| Diltiazem Hydrochloride Extended-Release Tablets | 13 | 12.7 | 12.7 |
| Exemestane | 23 | 12.0 | 12.0 |
| Extended Phenytoin Sodium | 15 | 9.9 | 9.9 |
| Denosumab | 167 | 9.9 | 9.9 |
| Anastrozole Tablets | 17 | 8.8 | 8.8 |
| Epoetin Alfa | 9 | 8.4 | 8.4 |
| Anastrozole | 25 | 7.6 | 7.6 |
| Raloxifene Hydrochloride | 10 | 7.6 | 7.6 |
| Sunitinib Malate | 26 | 7.4 | 7.4 |
| Zonisamide | 9 | 6.7 | 6.7 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate | 5 | 6.1 | 6.1 |
| Nicotine Polacrilex | 21 | 6.1 | 6.1 |
| Thalidomide | 18 | 5.4 | 5.4 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide | 4 | 4.4 | 4.4 |
| Ocrelizumab | 24 | 4.3 | 4.3 |
| Romosozumab-Aqqg | 5 | 4.1 | 4.1 |
| Teriparatide | 33 | 3.3 | 3.3 |
| Cabozantinib | 13 | 3.0 | 3.0 |
| Emtricitabine And Tenofovir Alafenamide | 3 | 2.9 | 2.9 |
| Axitinib | 5 | 2.8 | 2.8 |
| Lifitegrast | 4 | 2.7 | 2.7 |
| Abaloparatide | 7 | 2.6 | 2.6 |
| Bimekizumab | 4 | 2.1 | 2.1 |